Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic genotype 3 HCV infection (≥ 6 months)~* Presence of cirrhosis~* HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen~* Use of protocol specified methods of contraception~Key Exclusion Criteria:~* Current or prior history of clinically significant illness that may interfere with participation in the study~* Screening ECG with clinically significant abnormalities~* Laboratory parameters outside the acceptable range at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Type: EXPERIMENTAL): SOF/VEL/VOX tablet for 8 weeks
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL tablet for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).